Relapsed acute myeloid leukemia in children and adolescents: current treatment options and future strategies

Area of Science:

• Hematology
• Pediatric Oncology
• Cancer Genomics

Background:

• Pediatric acute myeloid leukemia (AML) arises from hematopoietic precursor cells, exhibiting significant heterogeneity.
• Despite survival improvements, preventing and managing relapse remain critical challenges, affecting approximately 25% of young patients.
• Relapsed pediatric AML carries a poor prognosis, necessitating novel therapeutic approaches beyond conventional chemotherapy.

Purpose of the Study:

• To review current and emerging therapies for relapsed pediatric acute myeloid leukemia.
• To highlight advancements in understanding the pathophysiology of relapsed AML.
• To emphasize the importance of clinical trials for developing new treatments.

Main Methods:

• Literature review of current and emerging therapies for relapsed pediatric AML.
• Analysis of recent research on the genomic, epigenomic, metabolomic, and immunologic aspects of relapsed AML.
• Examination of ongoing and planned multinational clinical trials.

Main Results:

• Conventional salvage chemotherapy regimens show limited efficacy and significant toxicity in heavily pretreated patients.
• A deeper understanding of relapsed AML pathophysiology is enabling the development of targeted, biologically rational agents.
• Multinational clinical trials are crucial for evaluating novel therapies and improving patient access.

Conclusions:

• Biologically targeted agents are essential for improving outcomes in relapsed pediatric AML.
• Increased participation in clinical trials is vital for advancing treatment options.
• Future strategies will likely involve a combination of novel agents and supportive care tailored to individual patient profiles.